Perrigo Company plc Long-term Line of Credit
Perrigo Company plc (PRGO) had Long-term Line of Credit of $0 as of 2017-12-31, per its 10-K filed 2018-03-01.
Discontinued › Balance Sheet › Liabilities › Long-Term Debt, Unclassified
us-gaap:LineOfCredit · last filed 2018-03-01
- 2017-12-31: Long-term Line of Credit $0.00.
- 2016-12-31: Long-term Line of Credit $0.00.
- 2016-10-01: Long-term Line of Credit $0.00.
- 2016-07-02: Long-term Line of Credit $0.00.
| Period end | Long-term Line of Credit | Long-term Line of Credit as first filed |
|---|---|---|
| 2017-12-31 | $0.00 10-K · filed 2018-03-01 | |
| 2016-12-31 | $0.00 10-K · filed 2018-03-01 | |
| 2016-10-01 | $0.00 10-Q/A · filed 2017-05-23 | |
| 2016-07-02 | $0.00 10-Q/A · filed 2017-05-22 | |
| 2016-04-02 | $0.00 10-Q/A · filed 2017-05-22 | |
| 2015-12-31 | $680.00M 10-Q/A · filed 2017-05-23 | |
| 2015-06-27 | $680.00M 10-K · filed 2018-03-01 | $0.00 10-KT · filed 2016-02-25 |
| 2014-06-28 | $0.00 10-KT · filed 2016-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |